DUSA Pharmaceuticals, Inc.(R) Announces Third Quarter Financial Results and Corporate Highlights Conference Call

Thursday, November 5, 2009 General News J E 4

WILMINGTON, Mass., Nov. 3 DUSA Pharmaceuticals, Inc. (Nasdaq: DUSA) announces that its corporate highlights and third quarter financial results press release will be issued on Friday, November 6 at 6:30 a.m. to be followed by a conference call at 8:30 a.m.

The call will be accessible on our web site approximately six hours following the call at

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc.(® )is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan(®) Photodynamic Therapy technology platform, and complementary dermatology products. Levulan( )PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses of the face and scalp. DUSA also markets other dermatology products, including ClindaReach(®). DUSA is researching Levulan PDT for the treatment of AKs and the prevention of new non-melanoma skin cancer in chronically immunosuppressed solid organ transplant recipients. DUSA is based in Wilmington, Mass. Please visit our web site at

Friday, November 6 - 8:30 a.m. E.T. If calling from the US or Canada use the following toll-free number: 800.647.4314 Password - DUSA For International callers use 502.498.8422 A recorded replay of the call will be available approximately 15 minutes following the call North American callers 877.863.0350 International callers 858.244.1268

SOURCE DUSA Pharmaceuticals, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
VIVUS Announces Promotion of Peter Tam to Presiden...
E Cigarettes May Be More Effective Than Swine Flu ...